MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

BRD-6929

CAS No. : 849234-64-6

MCE 站：BRD-6929

产品活性：BRD-6929 是 I 类组蛋白去乙酰化酶 HDAC1 和 HDAC2 的脑渗透性选择性抑制剂 (IC₅₀=?1 和 8 nM)。BRD-6929 对 HDAC1 和 HDAC2 有高亲和力 (K_i?=?0.2 和 1.5 nM)。BRD-6929 可用于情绪相关行为的研究。

研究领域：Cell Cycle/DNA Damage  |  Epigenetics  |  Anti-infection

作用靶点：HDAC  |  HIV

In Vitro: In vitro?IC₅₀ for HDAC1-9 by BRD-6929 using recombinant human HDAC enzymes and HDAC class-specific substrates. BRD-6929 and substrate are incubated for 180 min (HDAC1-3)?to control for HDAC1-3 inhibition, BRD-6929 is against HDAC1, HDAC2, HDAC3 and HDAC4-9 with IC₅₀s of 0.001 ?M, 0.008 ?M, 0.458 ?M and >30 ?M, respectively.
In vitro?binding affinity (K_i) and kinetics (half-life ‘T_1/2′?in minutes) for HDAC 1, 2 and 3 incubated with BRD-6929 (10 ?M), the K_i values are <0.2 nM, 1.5nM, and 270 nM for HDAC 1, 2 and 3, respectively. The T_1/2 values are >2400 mins, >4800 mins, and 1200 mins for HDAC 1, 2 and 3, respectively.
BRD-6929 (1 and 10 uM) does not cause an increase or decrease in overall cell number in brain region specific primary cultures. Additionally, BRD-6929 (10 uM) causes an increase in H4K12 acetylation in brain region specific primary cultures (striatum).
BRD-6929 (1-10 uM; 6 hours) causes a significant increase in H2B acetylation in primary neuronal cell cultures. BRD-6929 (1-20 uM; 24 hours) induces a dose-dependent acetylation of H4K12ac with an EC₅₀ of 7.2 ?M in cultured neurons.
BRD-6929 potentiates the efficacy of gnidimacrin (a PKC Agonist) against latent HIV-1.

In Vivo: BRD-6929 (intraperitoneal?injection; 45 mg/kg; single dose) exhibits a C_max, T_1/2 and AUC values of 17.7 μM, 7.2 hours, and 25.6 μM/L*hr, respectively in plasma. It shows a C_max, T_1/2 and AUC values of 0.83 μM, 6.4 hours, and 3.9 μM/L*hr, respectively in brain.
BRD-6929 (intraperitoneal?injection; 45 mg/kg; 10 days) acts as a deacetylase inhibitor in mouse brain. It significantly increases acetylation in each brain region by 1.5- to 2.0-fold compared to vehicle. The western blotting reveals that BRD-6929 significantly increases acetylation of histone H2B (tetra-acetylated), H3K9 and H4K12 in cortex, ventral striatum and hippocampus after the 10th daily treatment in adult male C57BL/6J mice.

相关产品：Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Cell Cycle/DNA Damage Compound Library  |  Epigenetics Compound Library  |  Histone Modification Research Compound Library  |  Antiviral Compound Library  |  CNS-Penetrant Compound Library  |  Anti-Aging Compound Library  |  Reprogramming Compound Library  |  Oxygen Sensing Compound Library  |  Anti-Cardiovascular Disease Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Doxorubicin hydrochloride  |  Chloroquine  |  5-Fluorouracil  |  Trichostatin A  |  4-Phenylbutyric acid  |  Valproic acid  |  (-)-Epigallocatechin Gallate  |  Entinostat  |  Sulforaphane  |  Romidepsin  |  Shikonin  |  Ivermectin  |  Ebselen  |  Kaempferol  |  Flavopiridol  |  Maraviroc  |  Hydroxyurea  |  Dimethyl fumarate  |  Baicalin  |  Probenecid  |  Ritonavir  |  Fasudil Hydrochloride  |  Lopinavir  |  Betulinic acid  |  RGFP966  |  Lamivudine  |  Tasquinimod

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。